# A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

> **NCT05109975** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Debiopharm International SA** · enrollment: 66 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Debio 0123

## Key facts

- **NCT ID:** NCT05109975
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-05
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109975, "A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05109975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*